189 related articles for article (PubMed ID: 16314644)
1. Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.
Eisenbeis CF; Lesinski GB; Anghelina M; Parihar R; Valentino D; Liu J; Nadella P; Sundaram P; Young DC; Sznol M; Walker MJ; Carson WE
J Clin Oncol; 2005 Dec; 23(34):8835-44. PubMed ID: 16314644
[TBL] [Abstract][Full Text] [Related]
2. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
3. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
Lesinski GB; Kondadasula SV; Crespin T; Shen L; Kendra K; Walker M; Carson WE
J Natl Cancer Inst; 2004 Sep; 96(17):1331-42. PubMed ID: 15339971
[TBL] [Abstract][Full Text] [Related]
4. IFN-alpha-2b-induced signal transduction and gene regulation in patient peripheral blood mononuclear cells is not enhanced by a dose increase from 5 to 10 megaunits/m2.
Zimmerer JM; Lehman AM; Ruppert AS; Noble CW; Olencki T; Walker MJ; Kendra K; Carson WE
Clin Cancer Res; 2008 Mar; 14(5):1438-45. PubMed ID: 18316567
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE
Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
[TBL] [Abstract][Full Text] [Related]
7. The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.
Martin del Campo SE; Levine KM; Mundy-Bosse BL; Grignol VP; Fairchild ET; Campbell AR; Trikha P; Mace TA; Paul BK; Jaime-Ramirez AC; Markowitz J; Kondadasula SV; Guenterberg KD; McClory S; Karpa VI; Pan X; Olencki TE; Monk JP; Mortazavi A; Tridandapani S; Lesinski GB; Byrd JC; Caligiuri MA; Shah MH; Carson WE
J Immunol; 2015 Sep; 195(5):1995-2005. PubMed ID: 26238487
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
[TBL] [Abstract][Full Text] [Related]
9. Phase II/pharmacodynamic trial of dose-intensive, weekly parenteral hydroxyurea and fluorouracil administered with interferon alfa-2a in patients with refractory malignancies of the gastrointestinal tract.
Wadler S; Damle S; Haynes H; Kaleya R; Schechner R; Berkenblit R; Ladner RD; Murgo A
J Clin Oncol; 1999 Jun; 17(6):1771-8. PubMed ID: 10561214
[TBL] [Abstract][Full Text] [Related]
10. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
[TBL] [Abstract][Full Text] [Related]
11. IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma.
Lesinski GB; Badgwell B; Zimmerer J; Crespin T; Hu Y; Abood G; Carson WE
J Immunol; 2004 Jun; 172(12):7368-76. PubMed ID: 15187113
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic intracavitary treatment with interferon alpha increases interferon gamma production by peripheral blood mononuclear cells in patients with superficial transitional cell carcinoma of the bladder.
Moltó L; Carballido J; Manzano L; Reyes E; Olivier C; Alvarez-Mon M
Br J Cancer; 1997; 75(12):1849-53. PubMed ID: 9192993
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
[TBL] [Abstract][Full Text] [Related]
14. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of weekly paclitaxel, 13- cis-retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies.
Thalasila A; Poplin E; Shih J; Dvorzhinski D; Capanna T; Doyle-Lindrud S; Beers S; Goodin S; Rubin E; DiPaola RS
Cancer Chemother Pharmacol; 2003 Aug; 52(2):119-24. PubMed ID: 12768320
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
Lenzi R; Rosenblum M; Verschraegen C; Kudelka AP; Kavanagh JJ; Hicks ME; Lang EA; Nash MA; Levy LB; Garcia ME; Platsoucas CD; Abbruzzese JL; Freedman RS
Clin Cancer Res; 2002 Dec; 8(12):3686-95. PubMed ID: 12473577
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
[TBL] [Abstract][Full Text] [Related]
18. A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies.
Ohno R; Yamaguchi Y; Toge T; Kinouchi T; Kotake T; Shibata M; Kiyohara Y; Ikeda S; Fukui I; Gohchi A; Sugiyama Y; Saji S; Hazama S; Oka M; Ohnishi K; Ohhashi Y; Tsukagoshi S; Taguchi T
Clin Cancer Res; 2000 Jul; 6(7):2661-9. PubMed ID: 10914707
[TBL] [Abstract][Full Text] [Related]
19. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.
Leonard JP; Sherman ML; Fisher GL; Buchanan LJ; Larsen G; Atkins MB; Sosman JA; Dutcher JP; Vogelzang NJ; Ryan JL
Blood; 1997 Oct; 90(7):2541-8. PubMed ID: 9326219
[TBL] [Abstract][Full Text] [Related]
20. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
Hauschild A; Weichenthal M; Rass K; Linse R; Ulrich J; Stadler R; Volkenandt M; Grabbe S; Proske U; Schadendorf D; Brockmeyer N; Vogt T; Rompel R; Kaufmann R; Kaatz M; Näher H; Mohr P; Eigentler T; Livingstone E; Garbe C
J Clin Oncol; 2009 Jul; 27(21):3496-502. PubMed ID: 19433681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]